Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New registry aims to clarify best use of Clot-Sucking catheter for lung blood clots

NCT ID NCT07650435

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is tracking 2000 patients with moderate to severe pulmonary embolism (blood clots in the lungs) who undergo a procedure called computer-aided vacuum thrombectomy, where a special tube sucks out the clot. Researchers want to see how well the procedure works and what complications occur, especially in patients who are sick but not at immediate risk of death. The goal is to provide better data for doctors and guideline groups like NICE.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
computer-aided vacuum thrombectomy catheter
What this could lead to
If successful, this could provide stronger evidence to support using this clot-removal procedure for patients with moderate to severe pulmonary embolism.
What could go wrong
This is an observational registry, not a controlled trial, so results may not prove cause and effect. The procedure carries risks like bleeding or vessel damage, and benefits may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 2,000 people

The number the study aims to enrol. It can still change while the study runs.

Started

May 2026

Expected to finish

Dec 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients with PE \<14 days and evidence of right heart strain

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Clinical signs and symptoms consistent with acute pulmonary embolism with duration of 14 days or less * Patients who present with computed tomography confirmed pulmonary embolism * Defined as intermediate or high-risk pulmonary embolism (according to European Society of Cardiology guidelines) * Date of computed tomography imaging from within a two-year period * Patient is greater than or equal to 18 years of age * Informed consent obtained * Evidence of cardiac dysfunction (either biochemical or imaging features of right heart strain) Exclusion Criteria: * Known serious, uncontrolled sensitivity to radiographic agents * Computed tomography not available to evaluate pulmonary embolism * Low-risk pulmonary embolism as defined by European Society of Cardiology guidelines * Current participation in another investigational drug or device study that may confound the results of this study. Studies requiring extended follow-up for products that were investigational but have since become commercially available are not considered investigational * Other medical, social, or psychological conditions that, in the opinion of the investigator, preclude the patient from appropriate consent, could limit the patient's ability to participate in the study, including compliance with follow-up requirements, or that could impact the scientific integrity of the study Inclusion Criteria: 1. Clinical signs and symptoms consistent with acute PE with duration of 14 days or less 2. Patients who present with CT confirmed PE 3. Defined as intermediate or high-risk PE (according to ESC guidelines1) 4. Date of CT imaging from within a two-year period 5. Patient is ≥ 18 years of age 6. Informed consent obtained 7. Evidence of cardiac dysfunction (Either biochemical or imaging features of RHS) Exclusion Criteria: * 1\. Known serious, uncontrolled sensitivity to radiographic agents 2. CT not available to evaluate PE 3. Low Risk PE as defined by ESC guidelines1 4. Current participation in another investigational drug or device study that may confound the results of this study. Studies requiring extended follow-up for products that were investigational but have since become commercially available are not considered investigational studies 5. Other medical, social, or psychological conditions that, in the opinion of the Investigator, precludes the patient from appropriate consent, could limit the patient's ability to participate in the study, including compliance with follow-up requirements, or that could impact the scientific integrity of the study

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Pulmonary embolism and thrombosis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • University Hospital Plymouth NHS Trust

    RECRUITING

    Plymouth, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.